Stayble Therapeutics is facing an eventful 2023 with expected data reporting from the phase IIb study with STA363. Patient recruitment was completed in 2022 and the six-month follow-up is predicted to be completed in the spring. In addition, the partnering discussions and preparations for phase III are now intensified. This includes a pre-IND meeting with the FDA, according to CEO Andreas Gerward.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/stayble-approaches-study-results-and-other-milestones/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-approaches-study-results-and-other-milestones,c3704411

(c) 2023 Cision. All rights reserved., source Press Releases - English